Neumentum is developing and plans to commercialize products that effectively treat pain, without the risks of abuse, misuse and diversion that may be found with opioids.

Neumentum’s lead product candidates, NTM-001 (pre-mixed bag ketorolac continuous infusion) and NTM-002 (IV continuous infusion with partial patient control) have the potential to maintain pain relief at an opioid level, reducing or eliminating the need for opioids.

NTM-001 is a Phase 3-ready IV formulation of Toradol (ketorolac) that is on track to receive FDA approval in 2021.

Injectable ketorolac has been used for more than 30 years, and is the most frequently administered non-opioid IV analgesic, with over 45 million doses given to patients with postsurgical pain in 2016.1 Ketorolac maintains pain relief at an opioid level, but is currently only available as IV or IM bolus injection. Neumentum plans to offer this proven treatment in novel, patented formulations which will be positioned to take advantage of major shifts away from opioids toward non-opioid alternatives.

Our earlier stage products include a novel intrathecal preparation of ketorolac and two novel non-opioid analgesic compounds that work similarly to acetaminophen (APAP), with the potential to be more potent and without the liver toxicity associated with APAP. Liver toxicity is a major problem in the United States and APAP overdose is the leading cause of acute liver failure.2 Still, APAP is an active ingredient in over 600 prescribed and over-the-counter products, including Percocet, Vicodin, Tylenol and Excedrin. Our products have the potential to replace acetaminophen products in the prescription and OTC markets, with increased potency and without the risk of adverse effects like liver failure.

Our Product Candidates

Disclaimer: These are investigational new drug candidates and are not approved for any indication in any markets.

  • [1] SHA PHAST audit, 12 months ending Mar 2017
  • [2] Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Lee WM et al. Hepatology, 2005 Dec; 42(6):1364-72